Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis (NVS) presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology Kidney Week 2024 ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4 ...

Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and ...

Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines: Basel Saturday, October 26, 2024, 14:00 Hrs [IST] This month, the NCCN ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.

The NCCN has updated its breast cancer guidelines, designating Novartis' Kisqali as a Category 1 preferred CDK4/6 inhibitor ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...

"The Phase III NATALEE trial demonstrated a noteworthy 25.1% reduction in the risk of recurrence among patients with HR+/HER2- stage II and III early breast cancer receiving adjuvant Kisqali ...

EAST HANOVER, N.J., Oct. 24, 2024 /PRNewswire/ -- This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for breast cancer were updated to recommend ribociclib (Kisqali ®) ...